Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

Key Takeaway: GRAIL, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company is dedicated to early cancer detection through innovative technologies. Live webcasts of the presentation will be available, and an archive will be accessible for 30 days post-event. GRAIL aims to alleviate the cancer burden globally.
Price reaction · baseline $50.35 (2026-02-24 close) · hit after-hours · 2 other GRAL headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is focused on early cancer detection, enhancing treatment outcomes.
  • The company utilizes advanced technologies like next-generation sequencing.
  • The presentation at a major healthcare conference highlights GRAIL's visibility.

Full Press Release Details

MENLO PARK, Calif.,Feb. 24, 2026/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website atinvestors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Frequently Asked Questions

When will GRAIL present at the conference?

GRAIL will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026.

How can I access the GRAIL presentation?

The presentation will be available via live and replay webcasts on GRAIL's investor relations website.

What is GRAIL's mission?

GRAIL's mission is to detect cancer early when it can be cured, using advanced technologies.

Where is GRAIL headquartered?

GRAIL is headquartered in Menlo Park, California.

Last updated: Feb 24, 2026